Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™…
Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived Picobodies™, the lead program, HSB-1940,…